PT-141
Also known as: Bremelanotide, Vyleesi
4.2
out of 5.0
An FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder in women, working through central nervous system pathways rather than vascular mechanisms.
Research Overview
Unlike phosphodiesterase inhibitors (such as sildenafil) that work through vascular mechanisms, PT-141 acts directly on the central nervous system. It activates MC4R receptors in the hypothalamus, modulating neural pathways involved in sexual arousal and desire. This central mechanism of action makes it effective for desire-based sexual dysfunction rather than purely physiological erectile dysfunction, representing a fundamentally different therapeutic approach.
FDA approval was based on Phase III clinical trials (RECONNECT studies) demonstrating statistically significant increases in sexual desire, arousal, and satisfaction scores compared to placebo. Research has shown that PT-141 increases the number of satisfying sexual events and improves measures of distress associated with low sexual desire. Studies in both male and female subjects have demonstrated its pro-sexual effects, though its current FDA indication is limited to premenopausal women with HSDD. Common side effects include nausea, flushing, and injection site reactions.
Documented Research Effects
Dosage & Protocol
Typical Dose Range
500 – 2000
mcg per dose
Frequency
As needed, 45 min before activity
Cycle Length
As needed, max 2x weekly
Common Vial Sizes
Calculate exact draw volumes and reconstitution steps.
Use CalculatorDosage information is for research reference only. Always follow established research protocols. Not medical advice.
Storage & Handling
Lyophilized Powder
Reconstituted Solution
Frequently Asked Questions
PT-141 (Bremelanotide) works through the central nervous system by activating melanocortin-4 receptors (MC4R) in the brain, specifically in the hypothalamus. Unlike PDE5 inhibitors (such as sildenafil/Viagra) that work on vascular blood flow, PT-141 acts directly on the neural pathways responsible for sexual arousal and desire. This makes it effective for both men and women, and it can work in cases where PDE5 inhibitors have failed.
PT-141 typically takes 30-60 minutes to take effect when administered via subcutaneous injection. The effects can last 6-12 hours, with peak activity occurring 1-3 hours after administration. It is recommended to administer it approximately 45 minutes before anticipated sexual activity. Effects may persist into the following day for some users.
The most common side effect is nausea, which occurs in approximately 40% of users, particularly at higher doses. Starting with a lower dose (500-750 mcg) and gradually increasing helps mitigate this. Other potential side effects include facial flushing, headache, and a transient increase in blood pressure. Taking an anti-nausea medication 30 minutes before the injection can help manage nausea in sensitive individuals.
Yes, PT-141 is one of the few treatments effective for female sexual dysfunction (hypoactive sexual desire disorder). In clinical trials, it significantly increased sexual desire and arousal in premenopausal women. The FDA-approved version (Vyleesi) is specifically indicated for women. Dosing for women is typically the same as for men (500-2000 mcg subcutaneous injection), though many women respond well at the lower end of the dose range.
PT-141 should not be used more than once in a 24-hour period and is generally recommended no more than 2 times per week. Frequent use can lead to diminished response due to melanocortin receptor desensitization. To maintain effectiveness, many users limit use to once weekly or as-needed dosing with adequate spacing between doses.
Community Reviews
All 72 reviews →No Reviews Yet
Community reviews for PT-141 are being collected. Check back soon.